Esperion Therapeutics ESPR Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The official record: Esperion Therapeutics’s 10-K, filed March 10, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's pre-tax income?
- Esperion Therapeutics (ESPR) reported pre-tax income of -$5.21M in Q4 2025.
- How has Esperion Therapeutics's pre-tax income changed year-over-year?
- Esperion Therapeutics's pre-tax income increased by 59.7% year-over-year, from -$12.94M to -$5.21M.
- What is the long-term trend for Esperion Therapeutics's pre-tax income?
- Over 2 years (2023 to 2025), Esperion Therapeutics's pre-tax income has grown at a -68.4% compound annual growth rate (CAGR), from -$209.25M to -$20.84M.
- What does pre-tax income mean?
- Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.